Schrödinger, Inc.
NMS: SDGRLive Quote
📈 ZcoreAI Score
Our AI model analyzes Schrödinger, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get SDGR Z-Score →About Schrödinger, Inc.
Healthcare
Health Information Services
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
📊 Fundamental Analysis
Schrödinger, Inc. demonstrates a profit margin of -40.4%, which is below the sector average, suggesting competitive pressure.
The company recently reported -1.2% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -26.3%, which indicates that capital utilization is currently under pressure.
At a current price of $11.37, SDGR currently trades near the bottom of its 52-week range (3%), indicating potential value or weakness (Range: $10.95 - $27.63).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$839.39M
Trailing P/E
--
Forward P/E
-8.24
Beta (5Y)
1.62
52W High
$27.63
52W Low
$10.95
Avg Volume
1.39M
Day High
Day Low